  0 Table of Contents |
 1 Home |
   1.1 Changes |
| 1.2 Dependencies |
| 1.3 References |
| 1.4 Adapting Guidelines for Country use |
 1.5 License |
| 2 Business Requirements |
| 2.1 Concepts |
| 2.2 Generic Personas |
| 2.3 User Scenarios |
| 2.4 Business Processes |
| 2.5 Data Dictionary |
| 2.6 Decision-support logic |
| 2.7 Indicator and Performance Metrics |
| 2.8 Functional Requirements |
| 2.9 Non-functional Requirements |
| 3 Data Models and Exchange |
| 3.1 System Actors |
| 3.2 Sequence Diagrams |
| 3.3 Transactions |
| 3.4 Indicators and Measures |
| 3.5 Codings |
| 4 Deployment |
| 4.1 Security and Privacy Considerations |
| 4.2 Testing |
| 4.3 Test Data |
| 4.4 Reference Implementations |
| 4.5 Downloads |
 5 Indices |
 5.1 Artifact Index |
| 5.1.1 HIV.B9.DT Schedule Follow-up Test |
| 5.1.2 HIV.B2.DT Check for signs of serious illness |
| 5.1.3 HIV.B9.DT Determine retest recommendation |
| 5.1.4 HIV.B2.DT Logic |
| 5.1.5 HIV.B7.DT Logic |
| 5.1.6 HIV.B9.DT Logic |
| 5.1.7 HIV.IND.11 Logic |
| 5.1.8 HIV.IND.12 Logic |
| 5.1.9 HIV.IND.13 Logic |
| 5.1.10 HIV.IND.14 Logic |
| 5.1.11 HIV.IND.15 Logic |
| 5.1.12 HIV.IND.16 Logic |
| 5.1.13 HIV.IND.18 Logic |
| 5.1.14 HIV.IND.19 Logic |
| 5.1.15 HIV.IND.2 Logic |
| 5.1.16 HIV.IND.20 Logic |
| 5.1.17 HIV.IND.21 Logic |
| 5.1.18 HIV.IND.22 Logic |
| 5.1.19 HIV.IND.24 Logic |
| 5.1.20 HIV.IND.25 Logic |
| 5.1.21 HIV.IND.27 Logic |
| 5.1.22 HIV.IND.28 Logic |
| 5.1.23 HIV.IND.29 Logic |
| 5.1.24 HIV.IND.3 Logic |
| 5.1.25 HIV.IND.30 Logic |
| 5.1.26 HIV.IND.31 Logic |
| 5.1.27 HIV.IND.32 Logic |
| 5.1.28 HIV.IND.33 Logic |
| 5.1.29 HIV.IND.34 Logic |
| 5.1.30 HIV.IND.35 Logic |
| 5.1.31 HIV.IND.37 Logic |
| 5.1.32 HIV.IND.38 Logic |
| 5.1.33 HIV.IND.39 Logic |
| 5.1.34 HIV.IND.4 Logic |
| 5.1.35 HIV.IND.40 Logic |
| 5.1.36 HIV.IND.41 Logic |
| 5.1.37 HIV.IND.42 Logic |
| 5.1.38 HIV.IND.43 Logic |
| 5.1.39 HIV.IND.44 Logic |
| 5.1.40 HIV.IND.45 Logic |
| 5.1.41 HIV.IND.46 Logic |
| 5.1.42 HIV.IND.47 Logic |
| 5.1.43 HIV.IND.48 Logic |
| 5.1.44 HIV.IND.49 Logic |
| 5.1.45 HIV.IND.5 Logic |
| 5.1.46 HIV.IND.50 Logic |
| 5.1.47 HIV.IND.51 Logic |
| 5.1.48 HIV.IND.52 Logic |
| 5.1.49 HIV.IND.53 Logic |
| 5.1.50 HIV.IND.54 Logic |
| 5.1.51 HIV.IND.55 Logic |
| 5.1.52 HIV.IND.56 Logic |
| 5.1.53 HIV.IND.57 Logic |
| 5.1.54 HIV.IND.58 Logic |
| 5.1.55 HIV.IND.59 Logic |
| 5.1.56 HIV.IND.6 Logic |
| 5.1.57 HIV.IND.60 Logic |
| 5.1.58 HIV.IND.61 Logic |
| 5.1.59 HIV.IND.62 Logic |
| 5.1.60 HIV.IND.63 Logic |
| 5.1.61 HIV.IND.64 Logic |
| 5.1.62 HIV.IND.65 Logic |
| 5.1.63 HIV.IND.66 Logic |
| 5.1.64 HIV.IND.67 Logic |
| 5.1.65 HIV.IND.68 Logic |
| 5.1.66 HIV.IND.69 Logic |
| 5.1.67 HIV.IND.7 Logic |
| 5.1.68 HIV.IND.70 Logic |
| 5.1.69 HIV.IND.71 Logic |
| 5.1.70 HIV.IND.72 Logic |
| 5.1.71 HIV.IND.73 Logic |
| 5.1.72 HIV.IND.74 Logic |
| 5.1.73 HIV.IND.75 Logic |
| 5.1.74 HIV.IND.76 Logic |
| 5.1.75 HIV.IND.77 Logic |
| 5.1.76 HIV.IND.78 Logic |
| 5.1.77 HIV.IND.79 Logic |
| 5.1.78 HIV.IND.8 Logic |
| 5.1.79 HIV.IND.80 Logic |
| 5.1.80 HIV.IND.81 Logic |
| 5.1.81 HIV.IND.82 Logic |
| 5.1.82 HIV.IND.83 Logic |
| 5.1.83 HIV.IND.84 Logic |
| 5.1.84 HIV.IND.85 Logic |
| 5.1.85 HIV.IND.86 Logic |
| 5.1.86 HIV.IND.87 Logic |
| 5.1.87 HIV.IND.88 Logic |
| 5.1.88 HIV.IND.89 Logic |
| 5.1.89 HIV.IND.9 Logic |
| 5.1.90 HIV.IND.90 Logic |
| 5.1.91 HIV.IND.91 Logic |
| 5.1.92 HIV.IND.92 Logic |
| 5.1.93 HIV.IND.93 Logic |
| 5.1.94 HIV.IND.94 Logic |
| 5.1.95 HIV.IND.95 Logic |
| 5.1.96 HIV.IND.96 Logic |
| 5.1.97 HIVCommon |
| 5.1.98 HIVConcepts |
| 5.1.99 HIVConceptsCustom |
| 5.1.100 HIVConfig |
| 5.1.101 HIVElements |
| 5.1.102 HIVEncounterElements |
| 5.1.103 HIVIndicatorElements |
| 5.1.104 WHOCommon |
| 5.1.105 WHOConcepts |
| 5.1.106 WHOElements |
| 5.1.107 WHOEncounterElements |
| 5.1.108 HIV.A Registration |
| 5.1.109 HIV.B HTS visit |
| 5.1.110 HIV.C PrEP visit |
| 5.1.111 HIV.Configuration |
| 5.1.112 HIV.D Care-Treatment |
| 5.1.113 HIV.D HIV-TB |
| 5.1.114 HIV.E-F PMTCT |
| 5.1.115 HIV.G Diagnostics |
| 5.1.116 HIV.H Follow-up |
| 5.1.117 HIV.I Referral |
| 5.1.118 HIV.Prevention |
| 5.1.119 HIV.Surveillance |
| 5.1.120 Assess for vaccine-preventable diseases |
| 5.1.121 Attempt to locate client |
| 5.1.122 Capture or update client history |
| 5.1.123 Capture or update client history |
| 5.1.124 Capture or update client history |
| 5.1.125 Capture or update infant's/child's history |
| 5.1.126 Capture or update mother's history |
| 5.1.127 Check for signs of serious illness |
| 5.1.128 Check for signs of treatment failure |
| 5.1.129 Check whether infant/child had HIV exposure |
| 5.1.130 Counsel |
| 5.1.131 Counsel on risk and prevention |
| 5.1.132 Counsel returning client |
| 5.1.133 Create new client record |
| 5.1.134 Determine clinical stage of HIV |
| 5.1.135 Determine reason for visit |
| 5.1.136 Determine reason for visit |
| 5.1.137 Determine reason for visit |
| 5.1.138 Determine recommended screenings and tests |
| 5.1.139 Determine recommended services |
| 5.1.140 Determine recommended tests |
| 5.1.141 Determine regimen and treatment options |
| 5.1.142 Diagnostics |
| 5.1.143 Diagnostics |
| 5.1.144 Emergency referral? |
| 5.1.145 Following up and contacting clients |
| 5.1.146 Gather client details |
| 5.1.147 Identify client for follow-up |
| 5.1.148 Immediately start infant on ART |
| 5.1.149 Offer other services |
| 5.1.150 Offer prevention options |
| 5.1.151 Offer sexual and reproductive health services |
| 5.1.152 Offer sexual and reproductive health services |
| 5.1.153 Offer voluntary partner and family services |
| 5.1.154 Perform other screenings |
| 5.1.155 Post-test package of services |
| 5.1.156 Prescribe |
| 5.1.157 Prescribe |
| 5.1.158 Prescribe or administer PrEP or PEP |
| 5.1.159 Prevent, screen, and manage comorbidities and coinfections |
| 5.1.160 Provide information to referral facility |
| 5.1.161 Provide post-test counselling |
| 5.1.162 Provide voluntary partner and family services |
| 5.1.163 Record infant's/child's final HIV diagnosis |
| 5.1.164 Record outreach and result |
| 5.1.165 Review sociodemographic data with client |
| 5.1.166 Schedule follow-up |
| 5.1.167 Schedule follow-up |
| 5.1.168 Schedule retest |
| 5.1.169 Screen for TB |
| 5.1.170 Suitable for PrEP or PEP? |
| 5.1.171 Take vital signs |
| 5.1.172 Take vital signs |
| 5.1.173 Test for HIV using testing algorithm |
| 5.1.174 Test infant/child for HIV using testing algorithm |
| 5.1.175 Test mother for HIV using testing algorithm |
| 5.1.176 Alternative PEP Backbone Prescription |
| 5.1.177 Alternative Third PEP Prescription |
| 5.1.178 Current PrEP Regimen Prescription |
| 5.1.179 Elevated HIV Risk Acquisition Condition |
| 5.1.180 HIV Prep Active |
| 5.1.181 HIV Status Condition |
| 5.1.182 HIV Status Observation |
| 5.1.183 HIV Test |
| 5.1.184 HivPatient |
| 5.1.185 On ART Medication Statement |
| 5.1.186 Patient Key Population Status |
| 5.1.187 Preferred PEP Backbone Prescription |
| 5.1.188 Preferred Third PEP Prescription |
| 5.1.189 PrEP Product Prescription |
| 5.1.190 Acute HIV infection symptoms ValueSet |
| 5.1.191 Administrative Area ValueSet |
| 5.1.192 Adverse event severity ValueSet |
| 5.1.193 Allergies ValueSet |
| 5.1.194 Alternative first-line ART regimen ValueSet |
| 5.1.195 Alternative PEP backbone regimen ValueSet |
| 5.1.196 Alternative second-line ART regimen ValueSet |
| 5.1.197 Alternative third PEP drug ValueSet |
| 5.1.198 Antiretroviral (ARV) drugs received prior to enrolment ValueSet |
| 5.1.199 ART regimen composition ValueSet |
| 5.1.200 ART regimen drug class ValueSet |
| 5.1.201 ART regimen prescribed ValueSet |
| 5.1.202 ART regimen ValueSet |
| 5.1.203 ART start type ValueSet |
| 5.1.204 ARV drug regimen received prior to enrolment ValueSet |
| 5.1.205 Assay number in testing strategy ValueSet |
| 5.1.206 Assay number in testing strategy ValueSet |
| 5.1.207 Asymptomatic bacteriuria (ASB) test result ValueSet |
| 5.1.208 Blood group and Rh factor ValueSet |
| 5.1.209 Cause of death of infant ValueSet |
| 5.1.210 Cause of death of mother ValueSet |
| 5.1.211 Cervical cancer colposcopy result ValueSet |
| 5.1.212 Cervical cancer diagnosis ValueSet |
| 5.1.213 Cervical cancer histopathology result ValueSet |
| 5.1.214 Cervical cancer primary screening test type ValueSet |
| 5.1.215 Cervical cancer screening outcome ValueSet |
| 5.1.216 Cervical cancer stage at diagnosis ValueSet |
| 5.1.217 Cervical cancer triage test type ValueSet |
| 5.1.218 Cervical cytology screening test result ValueSet |
| 5.1.219 Chlamydia trachomatis test type ValueSet |
| 5.1.220 Chlamydia trachomatis test type ValueSet |
| 5.1.221 Clinical stage at start of ART ValueSet |
| 5.1.222 Coinfection status at ART start ValueSet |
| 5.1.223 Communication preference(s) ValueSet |
| 5.1.224 Condom type ValueSet |
| 5.1.225 Confirmatory STI test result ValueSet |
| 5.1.226 Confirmatory STI test result ValueSet |
| 5.1.227 Confirmatory syphilis test type ValueSet |
| 5.1.228 Confirmatory syphilis test type ValueSet |
| 5.1.229 Contact method ValueSet |
| 5.1.230 Contraindications to PrEP usage ValueSet |
| 5.1.231 Counselling provided ValueSet |
| 5.1.232 Country of birth ValueSet |
| 5.1.233 Current ART regimen (first-, second-, or third-line) ValueSet |
| 5.1.234 Current ART regimen ValueSet |
| 5.1.235 Current medications ValueSet |
| 5.1.236 Current PrEP regimen ValueSet |
| 5.1.237 Delivery mode ValueSet |
| 5.1.238 Disease targeted ValueSet |
| 5.1.239 DSD ART model(s) ValueSet |
| 5.1.240 EID sample number ValueSet |
| 5.1.241 EID test number 1 test result ValueSet |
| 5.1.242 EID test number 2 test result ValueSet |
| 5.1.243 EID test number ValueSet |
| 5.1.244 Entry point for community-level testing ValueSet |
| 5.1.245 Entry point for facility-level testing ValueSet |
| 5.1.246 Entry point for facility-level testing ValueSet |
| 5.1.247 Existing chronic health conditions ValueSet |
| 5.1.248 Experience with PrEP ValueSet |
| 5.1.249 Facility transferred from ValueSet |
| 5.1.250 Facility where client first enrolled in HIV care ValueSet |
| 5.1.251 Family planning method used ValueSet |
| 5.1.252 Final diagnosis of HIV-exposed infant ValueSet |
| 5.1.253 First-line ART regimen under special circumstances ValueSet |
| 5.1.254 Gender of infant ValueSet |
| 5.1.255 Gender ValueSet |
| 5.1.256 General care activities recommended ValueSet |
| 5.1.257 Gonorrhoea test result ValueSet |
| 5.1.258 Gonorrhoea test result ValueSet |
| 5.1.259 HBsAg test result ValueSet |
| 5.1.260 HBsAg test result ValueSet |
| 5.1.261 HBV treatment regimen prescribed ValueSet |
| 5.1.262 HCV medicine type ValueSet |
| 5.1.263 HCV test result ValueSet |
| 5.1.264 HCV test result ValueSet |
| 5.1.265 HCV treatment regimen prescribed ValueSet |
| 5.1.266 HCV viral load test result ValueSet |
| 5.1.267 HCV viral load test result ValueSet |
| 5.1.268 Hepatitis B diagnosis ValueSet |
| 5.1.269 Hepatitis C diagnosis ValueSet |
| 5.1.270 Herpes simplex virus (HSV) test type ValueSet |
| 5.1.271 Herpes simplex virus (HSV) test type ValueSet |
| 5.1.272 HIV burden of the setting ValueSet |
| 5.1.273 HIV clinical stage ValueSet |
| 5.1.274 HIV diagnosing facility ValueSet |
| 5.1.275 HIV exposure type ValueSet |
| 5.1.276 HIV prevention intervention ValueSet |
| 5.1.277 HIV self-test distributed for use by ValueSet |
| 5.1.278 HIV self-test result ValueSet |
| 5.1.279 HIV serotype ValueSet |
| 5.1.280 HIV status of contact ValueSet |
| 5.1.281 HIV status of family member ValueSet |
| 5.1.282 HIV status of partner or contact ValueSet |
| 5.1.283 HIV status ValueSet |
| 5.1.284 HIV test result ValueSet |
| 5.1.285 HIV test type ValueSet |
| 5.1.286 HIV test type ValueSet |
| 5.1.287 HIV treatment outcome ValueSet |
| 5.1.288 HIV viral load specimen type ValueSet |
| 5.1.289 HIV-exposed infant reason for unknown final status ValueSet |
| 5.1.290 HPV-DNA cervical cancer screening test result ValueSet |
| 5.1.291 HPV16/18 test result ValueSet |
| 5.1.292 Infant feeding practice ValueSet |
| 5.1.293 Infant HIV status ValueSet |
| 5.1.294 Infant or child exposure to HIV ValueSet |
| 5.1.295 Intimate partner violence enquiry results ValueSet |
| 5.1.296 Invasive cervical cancer treatment method ValueSet |
| 5.1.297 Key population member type ValueSet |
| 5.1.298 Key population member type ValueSet |
| 5.1.299 Location ARV drugs received prior to enrolment ValueSet |
| 5.1.300 Marital Status ValueSet |
| 5.1.301 Maternal and child health service visit ValueSet |
| 5.1.302 Maternal HIV status at first ANC visit ValueSet |
| 5.1.303 Maternal HIV status ValueSet |
| 5.1.304 Maternal HIV test result ValueSet |
| 5.1.305 Maternal syphilis test result ValueSet |
| 5.1.306 Medication status ValueSet |
| 5.1.307 Medication/drug ValueSet |
| 5.1.308 Medications dispensed ValueSet |
| 5.1.309 Medications prescribed ValueSet |
| 5.1.310 Medications prescribed ValueSet |
| 5.1.311 Method of TB diagnosis ValueSet |
| 5.1.312 Monitoring examinations ValueSet |
| 5.1.313 Mycoplasma genitalium test type ValueSet |
| 5.1.314 Mycoplasma genitalium test type ValueSet |
| 5.1.315 Neisseria gonorrhoeae test type ValueSet |
| 5.1.316 Neisseria gonorrhoeae test type ValueSet |
| 5.1.317 New antiretroviral regimen after substitution within first-line regimen ValueSet |
| 5.1.318 New regimen after switch to second-line regimen ValueSet |
| 5.1.319 New regimen after switch to third-line regimen ValueSet |
| 5.1.320 New regimen(s) after substitution within second-line regimen ValueSet |
| 5.1.321 New regimen(s) after substitution within third-line regimen ValueSet |
| 5.1.322 Offer other clinical services ValueSet |
| 5.1.323 Offer other clinical services ValueSet |
| 5.1.324 Offer other clinical services ValueSet |
| 5.1.325 Optimal regimen for transition ValueSet |
| 5.1.326 Original first-line ART regimen ValueSet |
| 5.1.327 Other priority populations ValueSet |
| 5.1.328 Other support services ValueSet |
| 5.1.329 Other support services ValueSet |
| 5.1.330 Other support services ValueSet |
| 5.1.331 Outcome from outreach attempt ValueSet |
| 5.1.332 Partner HIV status (confirmed) ValueSet |
| 5.1.333 Partner HIV status (reported) ValueSet |
| 5.1.334 Partner HIV test result ValueSet |
| 5.1.335 Partner is from a key population ValueSet |
| 5.1.336 Past pregnancy complications ValueSet |
| 5.1.337 PEP history ValueSet |
| 5.1.338 Place of delivery ValueSet |
| 5.1.339 Preferred first-line ART regimen ValueSet |
| 5.1.340 Preferred PEP backbone regimen ValueSet |
| 5.1.341 Preferred second-line ART regimen ValueSet |
| 5.1.342 Preferred third PEP drug ValueSet |
| 5.1.343 Pregnancy intention in serodiscordant partnerships ValueSet |
| 5.1.344 Pregnancy outcome ValueSet |
| 5.1.345 Pregnant and breastfeeding status at ART start ValueSet |
| 5.1.346 PrEP dosing type ValueSet |
| 5.1.347 PrEP product prescribed ValueSet |
| 5.1.348 PrEP regimen prescribed ValueSet |
| 5.1.349 Preterm birth status ValueSet |
| 5.1.350 Preventing and treating coinfections ValueSet |
| 5.1.351 Prevention services offered and referrals ValueSet |
| 5.1.352 Prevention services offered and referrals ValueSet |
| 5.1.353 Prevention services offered and referrals ValueSet |
| 5.1.354 Probable route of transmission ValueSet |
| 5.1.355 Reason ART stopped ValueSet |
| 5.1.356 Reason ART stopped ValueSet |
| 5.1.357 Reason blood pressure reading not done ValueSet |
| 5.1.358 Reason for ARV drug regimen substitution ValueSet |
| 5.1.359 Reason for follow-up ValueSet |
| 5.1.360 Reason for HIV viral load test ValueSet |
| 5.1.361 Reason for PrEP visit ValueSet |
| 5.1.362 Reason for referral ValueSet |
| 5.1.363 Reason for regimen switch ValueSet |
| 5.1.364 Reason for switch to second-line regimen ValueSet |
| 5.1.365 Reason for switch to third-line regimen ValueSet |
| 5.1.366 Reason for visit ValueSet |
| 5.1.367 Reason for visit ValueSet |
| 5.1.368 Reason Hepatitis B test not conducted ValueSet |
| 5.1.369 Reason Hepatitis C test not done ValueSet |
| 5.1.370 Reason immunization was not provided ValueSet |
| 5.1.371 Reason malaria prophylaxis not provided ValueSet |
| 5.1.372 Reason syphilis test not done ValueSet |
| 5.1.373 Reason(s) for adherence problem ValueSet |
| 5.1.374 Reason(s) for adherence problem ValueSet |
| 5.1.375 Reason(s) for substitution within first-line regimen ValueSet |
| 5.1.376 Reason(s) for substitution within second-line regimen ValueSet |
| 5.1.377 Reason(s) for substitution within third-line regimen ValueSet |
| 5.1.378 Reasons for delayed ART initiation ValueSet |
| 5.1.379 Referred by ValueSet |
| 5.1.380 Referred through partner services ValueSet |
| 5.1.381 Risk factors, comorbidities and coinfections signs and symptoms ValueSet |
| 5.1.382 Screenings and diagnostics for PrEP users ValueSet |
| 5.1.383 Sex factor for estimating creatinine clearance ValueSet |
| 5.1.384 Sex partner's HIV treatment status ValueSet |
| 5.1.385 Sex ValueSet |
| 5.1.386 Sexual and reproductive health integrated services ValueSet |
| 5.1.387 Sexual and reproductive health integrated services ValueSet |
| 5.1.388 Sexual and reproductive health integrated services ValueSet |
| 5.1.389 Signs of serious illness ValueSet |
| 5.1.390 Signs of substantial risk of HIV infection ValueSet |
| 5.1.391 Signs of substantial risk of HIV infection ValueSet |
| 5.1.392 Site where positive HIV test confirmed ValueSet |
| 5.1.393 Source of gestational age ValueSet |
| 5.1.394 Source of information ValueSet |
| 5.1.395 Staging of liver disease ValueSet |
| 5.1.396 STI test result ValueSet |
| 5.1.397 STI test result ValueSet |
| 5.1.398 STI tested for ValueSet |
| 5.1.399 STI tested for ValueSet |
| 5.1.400 Symptoms of TB ValueSet |
| 5.1.401 Syndrome/STI diagnosed ValueSet |
| 5.1.402 Syndrome/STI diagnosed ValueSet |
| 5.1.403 Syphilis diagnosis ValueSet |
| 5.1.404 Syphilis test result ValueSet |
| 5.1.405 Syphilis test result ValueSet |
| 5.1.406 Syphilis test result ValueSet |
| 5.1.407 Syphilis test type ValueSet |
| 5.1.408 Syphilis test type ValueSet |
| 5.1.409 Syphilis test type ValueSet |
| 5.1.410 TB diagnosis result ValueSet |
| 5.1.411 TB diagnostic test category ValueSet |
| 5.1.412 TB preventive treatment (TPT) status ValueSet |
| 5.1.413 TB screening algorithm ValueSet |
| 5.1.414 TB screening result ValueSet |
| 5.1.415 TB status at ART start ValueSet |
| 5.1.416 TB treatment history ValueSet |
| 5.1.417 TB treatment outcome ValueSet |
| 5.1.418 TB treatment regimen composition ValueSet |
| 5.1.419 Test result of HIV assay 1 repeated ValueSet |
| 5.1.420 Test result of HIV assay 1 repeated ValueSet |
| 5.1.421 Test result of HIV assay 1 ValueSet |
| 5.1.422 Test result of HIV assay 1 ValueSet |
| 5.1.423 Test result of HIV assay 2 ValueSet |
| 5.1.424 Test result of HIV assay 2 ValueSet |
| 5.1.425 Test result of HIV assay 3 ValueSet |
| 5.1.426 Test result of HIV assay 3 ValueSet |
| 5.1.427 Test result of syphilis assay 1 repeated ValueSet |
| 5.1.428 Test result of syphilis assay 1 ValueSet |
| 5.1.429 Testing entry point ValueSet |
| 5.1.430 Time to start ART ValueSet |
| 5.1.431 Timing of adverse event ValueSet |
| 5.1.432 Timing of ART initiation ValueSet |
| 5.1.433 TPT regimen type ValueSet |
| 5.1.434 Transfer to facility ValueSet |
| 5.1.435 Treatment failure ValueSet |
| 5.1.436 Treatment method for cervical precancer lesions ValueSet |
| 5.1.437 Trichomonas vaginalis test type ValueSet |
| 5.1.438 Trichomonas vaginalis test type ValueSet |
| 5.1.439 Type of adverse VMMC event ValueSet |
| 5.1.440 Type of contact elicited ValueSet |
| 5.1.441 Type of contact or partner for partner services ValueSet |
| 5.1.442 Type of follow-up appointment ValueSet |
| 5.1.443 Type of follow-up appointment ValueSet |
| 5.1.444 Type of follow-up appointment ValueSet |
| 5.1.445 Type of hypertensive disorder ValueSet |
| 5.1.446 Type of iron supplement dosage provided ValueSet |
| 5.1.447 Type of specimen ValueSet |
| 5.1.448 Type of specimen ValueSet |
| 5.1.449 Type of treatment-limiting toxicity ValueSet |
| 5.1.450 Urine protein test result ValueSet |
| 5.1.451 Vaccination location ValueSet |
| 5.1.452 Vaccine brand ValueSet |
| 5.1.453 Vaccine type ValueSet |
| 5.1.454 VIA cervical cancer screening test result ValueSet |
| 5.1.455 WHO functional status ValueSet |
| 5.1.456 WHO HIV clinical stage condition or symptom ValueSet |
| 5.1.457 WHO HIV clinical stage condition or symptom ValueSet |
| 5.1.458 WHO SMART HIV Concepts CodeSystem |
| 5.1.459 Aggregate reporting and data use |
| 5.1.460 Care and treatment clinical visit |
| 5.1.461 Client |
| 5.1.462 Community health worker |
| 5.1.463 Data entry clerk |
| 5.1.464 Diagnostics |
| 5.1.465 District health information officer |
| 5.1.466 Example Alternative PEP Backbone Prescription |
| 5.1.467 Example Alternative Third PEP Prescription |
| 5.1.468 Example Current PrEP Regimen Prescription |
| 5.1.469 Example Elevated HIV Risk Condition |
| 5.1.470 Example HIV Key Population Observation |
| 5.1.471 Example HIV On ART Medication Statement |
| 5.1.472 Example HIV Positive Status Condition |
| 5.1.473 Example HIV Positive Status Observation |
| 5.1.474 Example HIV Test Observation for Positive Result |
| 5.1.475 Example Preferred PEP Backbone Prescription |
| 5.1.476 Example Preferred Third PEP Prescription |
| 5.1.477 Example PrEP Product Prescription |
| 5.1.478 ExampleHivPatient |
| 5.1.479 Following up and contacting clients |
| 5.1.480 HIV non Functional Requirements |
| 5.1.481 HIV testing services |
| 5.1.482 HIV.IND.11 OAMT coverage |
| 5.1.483 HIV.IND.12 Total person-years on OAMT |
| 5.1.484 HIV.IND.13 OAMT minimum duration |
| 5.1.485 HIV.IND.14 OAMT minimum dose |
| 5.1.486 HIV.IND.15 VMMC scale-up |
| 5.1.487 HIV.IND.16 VMMC adverse events |
| 5.1.488 HIV.IND.18 People living with HIV who know their HIV status (first 95) |
| 5.1.489 HIV.IND.19 HTS test volume and positivity |
| 5.1.490 HIV.IND.2 Total PrEP recipients |
| 5.1.491 HIV.IND.20 Individuals testing positive for HIV |
| 5.1.492 HIV.IND.21 Linkage to ART |
| 5.1.493 HIV.IND.22 HTS partner services |
| 5.1.494 HIV.IND.24 HTS linkage to prevention |
| 5.1.495 HIV.IND.25 HIV retesting coverage |
| 5.1.496 HIV.IND.27 People living with HIV on ART |
| 5.1.497 HIV.IND.28 Total attrition from ART |
| 5.1.498 HIV.IND.29 People living with HIV on ART who have suppressed viral load |
| 5.1.499 HIV.IND.3 PrEP coverage |
| 5.1.500 HIV.IND.30 New ART patients |
| 5.1.501 HIV.IND.31 Late ART initiation |
| 5.1.502 HIV.IND.32 Viral load testing coverage |
| 5.1.503 HIV.IND.33 Early viral load testing (at six months) |
| 5.1.504 HIV.IND.34 Appropriate second viral load test after adherence counselling |
| 5.1.505 HIV.IND.35 ARV toxicity prevalence |
| 5.1.506 HIV.IND.37 Viral suppression at labour and delivery |
| 5.1.507 HIV.IND.38 Early infant diagnosis (EID) coverage |
| 5.1.508 HIV.IND.39 Infant ARV prophylaxis coverage |
| 5.1.509 HIV.IND.4 Volume of PrEP prescribed |
| 5.1.510 HIV.IND.40 ART coverage in pregnant women |
| 5.1.511 HIV.IND.41 ART coverage in breastfeeding mothers |
| 5.1.512 HIV.IND.42 Final outcome of PMTCT |
| 5.1.513 HIV.IND.43 HIV prevalence among women attending ANC |
| 5.1.514 HIV.IND.44 TPT initiation |
| 5.1.515 HIV.IND.45 TPT completion |
| 5.1.516 HIV.IND.46 TB diagnostic testing type |
| 5.1.517 HIV.IND.47 People living with HIV with active TB disease |
| 5.1.518 HIV.IND.48 TB screening coverage among new ART patients |
| 5.1.519 HIV.IND.49 TB symptom-screened positive among new ART patients |
| 5.1.520 HIV.IND.5 Number of PEP recipients |
| 5.1.521 HIV.IND.50 TB testing among those symptom-screened positive |
| 5.1.522 HIV.IND.51 TB diagnosis among those tested for TB |
| 5.1.523 HIV.IND.52 TB treatment initiation among diagnosed |
| 5.1.524 HIV.IND.53 Multi-month ARV dispensing |
| 5.1.525 HIV.IND.54 Uptake of DSD ART models among people living with HIV |
| 5.1.526 HIV.IND.55 Coverage of DSD ART models among people living with HIV on ART |
| 5.1.527 HIV.IND.56 Retention in DSD ART models |
| 5.1.528 HIV.IND.57 Viral suppression among people living with HIV engaged in DSD ART models |
| 5.1.529 HIV.IND.58 Syphilis testing coverage, HIV prevention services |
| 5.1.530 HIV.IND.59 Syphilis testing coverage, HIV-positive clients |
| 5.1.531 HIV.IND.6 PEP completion |
| 5.1.532 HIV.IND.60 Syphilis testing coverage, pregnant women, first ANC visit |
| 5.1.533 HIV.IND.61 Syphilis testing coverage, pregnant women, any ANC visit |
| 5.1.534 HIV.IND.62 Syphilis test positivity, HIV prevention services |
| 5.1.535 HIV.IND.63 Syphilis test positivity, HIV-positive clients |
| 5.1.536 HIV.IND.64 Syphilis test positivity, pregnant women, first visit |
| 5.1.537 HIV.IND.65 Syphilis test positivity, pregnant women, any visit |
| 5.1.538 HIV.IND.66 Syphilis treatment coverage, HIV prevention services |
| 5.1.539 HIV.IND.67 Syphilis treatment coverage, HIV-positive clients |
| 5.1.540 HIV.IND.68 Syphilis treatment coverage, pregnant women, first ANC visit |
| 5.1.541 HIV.IND.69 Syphilis treatment coverage, pregnant women, any ANC visit |
| 5.1.542 HIV.IND.7 HIV in PEP recipients |
| 5.1.543 HIV.IND.70 Gonorrhoea testing coverage, HIV prevention services |
| 5.1.544 HIV.IND.71 Gonorrhoea testing coverage, HIV-positive clients |
| 5.1.545 HIV.IND.72 Gonorrhoea test positivity, HIV prevention services |
| 5.1.546 HIV.IND.73 Gonorrhoea test positivity, HIV-positive clients |
| 5.1.547 HIV.IND.74 Gonorrhoea treatment coverage, HIV prevention services |
| 5.1.548 HIV.IND.75 Gonorrhoea treatment coverage, HIV-positive clients |
| 5.1.549 HIV.IND.76 Presence of STI syndrome, HIV prevention services |
| 5.1.550 HIV.IND.77 Presence of STI syndrome, HIV-positive clients |
| 5.1.551 HIV.IND.78 Repeat diagnosis of STI syndrome, HIV prevention services |
| 5.1.552 HIV.IND.79 Repeat diagnosis of STI syndrome, HIV-positive clients |
| 5.1.553 HIV.IND.8 NSP coverage |
| 5.1.554 HIV.IND.80 HBV test coverage, HIV prevention services |
| 5.1.555 HIV.IND.81 HBV test coverage, HIV-positive clients |
| 5.1.556 HIV.IND.82 HBV test coverage, pregnant women |
| 5.1.557 HIV.IND.83 HCV test coverage, HIV prevention services |
| 5.1.558 HIV.IND.84 HCV test coverage, HIV-positive clients |
| 5.1.559 HIV.IND.85 HBsAg positivity, HIV prevention services |
| 5.1.560 HIV.IND.86 HBsAg positivity, HIV-positive clients |
| 5.1.561 HIV.IND.87 HBsAg positivity, pregnant women |
| 5.1.562 HIV.IND.88 HCV positivity, HIV prevention services |
| 5.1.563 HIV.IND.89 HCV positivity, HIV-positive clients |
| 5.1.564 HIV.IND.9 Regular NSP access |
| 5.1.565 HIV.IND.90 HBV treatment among people living with HIV |
| 5.1.566 HIV.IND.91 HCV treatment among people living with HIV |
| 5.1.567 HIV.IND.92 HCV cured among people living with HIV |
| 5.1.568 HIV.IND.93 Cervical cancer screening |
| 5.1.569 HIV.IND.94 Pre-invasive cervical disease treatment |
| 5.1.570 HIV.IND.95 Invasive cervical cancer treatment |
| 5.1.571 HIV.IND.96 Cervical cancer survival |
| 5.1.572 Key populations |
| 5.1.573 Lab technician |
| 5.1.574 Nurse |
| 5.1.575 Pharmacist |
| 5.1.576 Physician |
| 5.1.577 PrEP visit |
| 5.1.578 Referral |
| 5.1.579 Registration |
| 5.1.580 Special population client |
| 5.1.581 Specialist medical doctor |
| 5.1.582 Trained lay provider |
| 5.1.583 Trained non-physician clinician |
| 5.2 Mappings |